Epilepsy Breakthrough: A landmark study published in The New England Journal of Medicine (2017) demonstrated that CBD could reduce seizure frequency in children with Dravet syndrome, a severe form of epilepsy. This research has changed lives and informed ongoing clinical trials exploring further therapeutic applications of CBD.
The use of cannabis as a treatment for epilepsy has a rich and diverse history, spanning multiple cultures and centuries. The earliest documented use of cannabis for medical purposes can be traced back to ancient China around 2000 BCE. Emperor Shen Nung, often regarded as the father of Chinese medicine, included cannabis in his pharmacopeia, recommending it for various ailments, including conditions resembling epilepsy. This early reference highlights the long-standing recognition of cannabis's potential therapeutic properties.
In ancient India, cannabis was integral to traditional Ayurvedic medicine. The Atharvaveda, an ancient Indian text dating back over 3,000 years, mentions cannabis as one of the "five sacred plants" and documents its use in treating various health issues, including those that may correspond to modern understandings of epilepsy. The cultural and religious significance of cannabis in India also played a role in its medicinal applications, as it was believed to possess divine and healing properties.
The Middle Eastern medical tradition also recognized cannabis's medicinal value. The renowned Persian physician Avicenna, in his seminal work "The Canon of Medicine," described the use of cannabis for treating epilepsy and other neurological disorders. Avicenna's writings, which were highly influential in both the Eastern and Western medical worlds, provided a detailed account of cannabis's therapeutic potential.
In the 19th century, the medical use of cannabis gained prominence in Western medicine, largely due to the work of Dr. William O'Shaughnessy. An Irish physician working in India, O'Shaughnessy conducted extensive research on cannabis and published a groundbreaking paper in 1843 that highlighted its potential for treating a variety of conditions, including seizures. His findings played a crucial role in introducing cannabis to Western medical practices, where it was used for various therapeutic purposes throughout the 19th and early 20th centuries.
However, the 20th century saw a decline in the medical use of cannabis due to increasing regulation and criminalization. The passage of laws such as the Marihuana Tax Act of 1937 in the United States significantly restricted access to cannabis, leading to a decline in its use and research. Despite these challenges, anecdotal evidence and limited clinical studies continued to suggest that cannabis might possess anticonvulsant properties.
The discovery of the endocannabinoid system in the early 1990s marked a pivotal moment in the scientific understanding of cannabis. This system, which includes cannabinoid receptors throughout the human body, is crucial in regulating various physiological processes, including mood, pain, and seizure activity. The identification of this system provided a biological basis for the therapeutic effects of cannabinoids, spurring renewed interest in cannabis research.
A significant milestone in the modern history of cannabis and epilepsy was the case of Charlotte Figi, a young girl suffering from Dravet syndrome, a severe and intractable form of epilepsy. In the early 2010s, Charlotte's parents, in collaboration with doctors, began using a high-CBD cannabis extract to treat her seizures. The treatment led to a dramatic reduction in seizure frequency, from hundreds per week to just a few per month. Charlotte's story gained widespread media attention and highlighted the potential of CBD as a treatment for epilepsy, sparking a resurgence in clinical research and public interest.
This renewed focus led to several clinical trials investigating the efficacy and safety of CBD in treating various forms of epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. These studies provided robust evidence supporting the use of CBD as an effective treatment option, culminating in the FDA's approval of Epidiolex in 2018. Epidiolex, derived from CBD, became the first cannabis-derived medication approved by the FDA for the treatment of epilepsy, marking a significant milestone in the recognition of cannabis's medical potential.
If you need help finding your best cannabis regimen, please make an appointment with a cannabis pharmacist at greenbridgehealth.com and check out our resource pages.
If you want to get your MMJ card for the first time or just renew it, please go to greenbridgesociety.com for the best service and lowest prices.